Nanocrystal quantum dot-conjugated anti-myeloperoxidase antibody as the detector of activated neutrophils

IEEE Transactions on Nanobioscience

Volumn 6, Issue 4, 2007, Pages 341-345

  Hoshino, Akiyoshi ^a,b,c   Nagao, Tomokazu ^c,d   Nakasuga, Akira ^e   Ishida Okawara, Akiko ^c   Suzuki, Kazuo ^c,d   Yasuhara, Masato ^b   Yamamoto, Kenji ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e SEKISUI CHEMICAL CO LTD   (Japan)

Author keywords

Bioimaging; Diagnosis of activated neutrophils; Quantum dot conjugated with antibody

Indexed keywords

BIOIMAGING; DIAGNOSIS OF ACTIVATED NEUTROPHILS; MYELOPEROXIDASE (MPO); QUANTUM DOT CONJUGATED WITH ANTIBODY;

ANTIBODIES; ENZYME ACTIVITY; ENZYME KINETICS; FLOW CYTOMETRY; FLUORESCENCE;

SEMICONDUCTOR QUANTUM DOTS;

CYTOKINE; ENZYME ANTIBODY; FC RECEPTOR; MYELOPEROXIDASE; MYELOPEROXIDASE ANTIBODY; NANOCRYSTAL; QUANTUM DOT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BIOMEDICINE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, SURFACE; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; NANOPARTICLES; NEUTROPHIL ACTIVATION; NEUTROPHILS; PEROXIDASE; QUANTUM DOTS; STAINING AND LABELING;

EID: 36749094721     PISSN: 15361241     EISSN: None     Source Type: Journal    
DOI: 10.1109/TNB.2007.909008     Document Type: Article

References (38)

1. W. L. Gross, W. H. Schmitt, and E. Csernok, "ANCA and associated diseases: Immunodiagnostic and pathogenetic aspects," Clin. Exp. Immunol, vol. 91, pp. 1-12, 1993.
2. P. Lesavre, L. H. Noel, S. Gayno, P. Nusbaum, D. Reumaux, S. Erlinger, J. P. Grunfeld, and L. Halbwachs-Mecarelli, "Atypical autoantigen targets of perinuclear antineutrophil cytoplasm antibodies (P-ANCA): Specificity and clinical associations," J. Autoimmun., vol. 6, pp. 185-195, 1993.
3. E. Muso, T. Ito-Ihara, T. Ono, E. Imai, K. Yamagata, A. Akamatsu, and K. Suzuki, "Intravenous immunoglobulin (ivig) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in japan," Jpn. J. Infect. Dis., vol. 57, pp. S17-18, 2004.
4. J. C. Jennette et al., "Nomenclature of systemic vasculitides. proposal of an international consensus conference," Arthritis Rheum., vol. 37, pp. 187-192, 1994.
5. E. Csernok, "Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides," Autoimmun. Rev., vol. 2, pp. 158-164, 2003.
6. M. A. Little, C. L. Smyth, R. Yadav, L. Ambrose, H. T. Cook, S. Nourshargh, and C. D. Pusey, "Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo," Blood, vol. 106, pp. 2050-2058, 2005.
7. C. O. Savage, B. E. Pottinger, G. Gaskin, C. D. Pusey, and J. D. Pearson, "Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells," Am. J. Pathol., vol. 141, pp. 335-342, 1992.
8. D. J. Radford, J. M. Lord, and C. O. Savage, "The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation," Clin. Exp. Immunol., vol. 118, pp. 171-179, 1999.
9. D. J. Radford, C. O. Savage, and G. B. Nash, "Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion," Arthritis Rheum., vol. 43, pp. 1337-1345, 2000.
10. A. Ben-Smith, S. K. Dove, A. Martin, M. J. Wakelam, and C. O. Savage, "Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: Comparison with conventional fcgamma receptor ligation," Blood, vol. 98, pp. 1448-1455, 2001.
11. L. Harper, P. Cockwell, D. Adu, and C. O. Savage, "Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis," Kidney Int., vol. 59, pp. 1729-1738, 2001.
12. Y. M. van der Geld, W. Oost-Kort, P. C. Limburg, U. Specks, and C. G. Kallenberg, "Recombinant proteinase 3 produced in different expression systems: Recognition by anti-pr3 antibodies," J. Immunol. Methods, vol. 244, pp. 117-131, 2000.
13. E. Csernok, M. Ernst, W. Schmitt, D. F. Bainton, and W. L. Gross, "Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo," Clin. Exp. Immunol., vol. 95, pp. 244-250, 1994.
14. D. R. Larson, W. R. Zipfel, R. M. Williams, S. W. Clark, M. Bruchez, F. W. Wise, and W. W. Webb, "Water-soluble quantum dots for multiphoton fluorescence imaging in vivo," Sci, vol. 300, pp. 1434-1436, 2003.
15. W. C. Chan and S. Nie, "Quantum dot bioconjugates for ultrasensitive nonisotopic detection," Sci, vol. 281, pp. 2016-2018, 1998.
16. T. C. Harman, P. J. Taylor, M. P. Walsh, and B. E. LaForge, "Quantum dot superlattice thermoelectric materials and devices," Sci, vol. 297, no. 5590, pp. 2229-2232, Sep. 27, 2002.
17. X. Wu, H. Liu, J. Liu, K. N. Haley, J. A. Treadway, J. P. Larson, N. Ge, F. Peale, and M. P. Bruchez, "Immunofluorescent labeling of cancer marker her2 and other cellular targets with semiconductor quantum dots," Nature Biotechnol., vol. 21, pp. 41-46, 2003.
18. B. Dubertret, P. Skourides, D. J. Norris, V. Noireaux, A. H. Brivanlou, and A. Libchaber, "In vivo imaging of quantum dots encapsulated in phospholipid micelles," Science, vol. 298, pp. 1759-1762, 2002.
19. J. K. Jaiswal, H. Mattoussi, J. M. Mauro, and S. M. Simon, "Long-term multiple color imaging of live cells using quantum dot bioconjugates," Nature Biotechnol., vol. 21, pp. 47-51, 2003.
20. A. Hoshino, K. Hanaki, K. Suzuki, and K. Yamamoto, "Applications of t-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body," Biochem Biophys Res. Commun., vol. 314, pp. 46-53, 2004.
21. A. Hoshino, Y. I. Kawamura, M. Yasuhara, N. Toyama-Sorimachi, K. Yamamoto, A. Matsukawa, S. A. Lira, and T. Dohi, "Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions," J. Immunol., vol. 178, pp. 5296-5304, 2007.
22. A. Hoshino, K. Fujioka, T. Oku, S. Nakamura, M. Suga, Y. Yamaguchi, K. Suzuki, M. Yasuhara, and K. Yamamoto, "Quantum dots targeted to the assigned organelle in living cells," Microbiol. Immunol., vol. 48, pp. 985-994, 2004.
23. A. Hoshino, K. Fujioka, N. Manabe, S. Yamaya, Y. Goto, M. Yasuhara, and K. Yamamoto, "Simultaneous multicolor detection system of the single-molecular microbial antigen with total internal reflection fluorescence microscopy," Microbiol. Immunol., vol. 49, pp. 461-470, 2005.
24. S. Yamamoto, N. Manabe, K. Fujioka, A. Hoshino, and K. Yamamoto, "Visualizing vitreous using quantum dots as imaging reagents," IEEE Trans. Nanobiosci., vol. 6, no. 1, pp. 94-98, Mar. 2007.
25. B. O. Dabbousi, J. Rodriguez-Viejo, F. V. Mikulec, J. R. Heine, H. Mattoussi, R. Ober, K. F. Jensen, and M. Bawendi, "(CdSe)ZnS core-shell quantum dots: Synthesis and characterization of a size series of highly luminescent nanocrystallites," J. Phys. Chem., vol. 101, pp. 9463-9475, 1997.
26. M. A. Hines and P. Guyot-Sionnest, "Synthesis and characterization of strongly luminescing ZnS-capped cdse nanocrystals," J. Phys. Chem., vol. 100, pp. 468-471, 1996.
27. A. Hoshino, K. Fujioka, T. Oku, M. Suga, Y. F. Sasaki, T. Ohta, M. Yasuhara, K. Suzuki, and K. Yamamoto, "Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification," Nano Lett., vol. 4, pp. 2163-2169, 2004.
28. Y. Aratani, F. Kura, H. Watanabe, H. Akagawa, Y. Takano, K. Suzuki, N. Maeda, and H. Koyama, "Differential host susceptibility to pulmonary infections with bacteria and fungi in mice deficient in myeloperoxidase," J. Infect. Dis., vol. 182, pp. 1276-1279, 2000.
29. Y. Aratani, F. Kura, H. Watanabe, H. Akagawa, Y. Takano, K. Suzuki, M. C. Dinauer, N. Maeda, and H. Koyama, "Critical role of myeloperoxidase and nicotinamide adenine dinucleotide phosphate-oxidase in high-burden systemic infection of mice with candida albicans," J. Infect Dis., vol. 185, pp. 1833-1837, 2002.
30. A. Ishida-Okawara, T. Oharaseki, K. Takahashi, Y. Hashimoto, Y. Aratani, H. Koyama, N. Maeda, S. Naoe, and K. Suzuki, "Contribution of myeloperoxidase to coronary artery vasculitis associated with MPO-ANCA production," Inflammation, vol. 25, pp. 381-387, 2001.
31. R. L. Ornberg, T. F. Harper, and H. Liu, "Western blot analysis with quantum dot fluorescence technology: A sensitive and quantitative method for multiplexed proteomics," Nature Methods, vol. 2, pp. 79-81, 2005.
32. A. Fujii, K. Tomizawa, Y. Arimura, T. Nagasawa, Y. Y. Ohashi, T. Hiyama, S. Mizuno, and K. Suzuki, "Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis," Clin. Nephrol., vol. 53, pp. 242-252, 2000.
33. A. Hoshino, T. Nagao, T. Ito-Ihara, A. Ishida-Okawara, K. Uno, E. Muso, N. Nagi-Miura, N. Ohno, K. Tokunaka, S. Naoe, H. Hashimoto, M. Yasuhara, K. Yamamoto, and K. Suzuki, "Trafficking of qd-conjugated MPO-ANCA in murine systemic vasculitis and glomerulonephritis model mice," Microbiol. Immunol., vol. 51, pp. 551-566, 2007.
34. K. Suzuki and T. Okazaki, "Contribution of myeloperoxidase in vasculitis development," Jpn. J. Infect. Dis., vol. 57, pp. S2-3, 2004.
35. L. Harper, D. Radford, T. Plant, M. Drayson, D. Adu, and C. O. Savage, "IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than igg from proteinase 3-antineutrophil cytosplasmic antibody-positive patients," Arthritis Rheum., vol. 44, pp. 921-930, 2001.
36. T. Ito-Ihara, T. Ono, F. Nogaki, K. Suyama, M. Tanaka, S. Yonemoto, A. Fukatsu, T. Kita, K. Suzuki, and E. Muso, "Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis," Nephron. Clin. Pract., vol. 102, pp. 35-42, 2006.
37. Y. Kawai, A. I. Okawarab, H. Okuyama, F. Kura, and K. Suzuki, "Modulation of chemotaxis, O(2)(-) production and myeloperoxidase release from human polymorphonuclear leukocytes by the ornithine-containing lipid and the serineglycine-containing lipid of flavobacterium," FEMS Immunol. Med. Microbiol., vol. 28, pp. 205-209, 2000.
38. A. Hoshino, T. Ito-Ihara, A. Ishida-Okawara, E. Muso, K. Yamamoto, and K. Suzuki, "Detection of neutrophil MPO in patient with rapidly progressive glumerulonephritis," Rinsho Kensa, vol. 50, pp. 1409-1415, 2006.